Vaxcyte, Inc. (PCVX)

Vaxcyte Statistics

Total Valuation

Vaxcyte has a market cap or net worth of $5.48 billion. The enterprise value is $3.91 billion.

Market Cap	5.48B
Enterprise Value	3.91B

Important Dates

The next estimated earnings date is Wednesday, November 5, 2025, after market close.

Earnings Date	Nov 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Vaxcyte has 129.82 million shares outstanding. The number of shares has increased by 22.51% in one year.

Current Share Class	129.82M
Shares Outstanding	129.82M
Shares Change (YoY)	+22.51%
Shares Change (QoQ)	+0.25%
Owned by Insiders (%)	0.78%
Owned by Institutions (%)	106.24%
Float	116.84M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.78
P/TBV Ratio	1.79
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 11.11, with a Debt / Equity ratio of 0.03.

Current Ratio	11.11
Quick Ratio	10.76
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -21.65% and return on invested capital (ROIC) is -17.15%.

Return on Equity (ROE)	-21.65%
Return on Assets (ROA)	-16.44%
Return on Invested Capital (ROIC)	-17.15%
Return on Capital Employed (ROCE)	-22.51%
Revenue Per Employee	n/a
Profits Per Employee	-$1.32M
Employee Count	414
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -62.33% in the last 52 weeks. The beta is 1.12, so Vaxcyte's price volatility has been higher than the market average.

Beta (5Y)	1.12
52-Week Price Change	-62.33%
50-Day Moving Average	35.76
200-Day Moving Average	46.84
Relative Strength Index (RSI)	60.43
Average Volume (20 Days)	1,833,394

Short Selling Information

The latest short interest is 10.01 million, so 7.71% of the outstanding shares have been sold short.

Short Interest	10.01M
Short Previous Month	11.08M
Short % of Shares Out	7.71%
Short % of Float	8.57%
Short Ratio (days to cover)	4.66

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-709.11M
Pretax Income	-547.50M
Net Income	-547.50M
EBITDA	-698.62M
EBIT	-709.11M
Earnings Per Share (EPS)	-$4.13

Balance Sheet

The company has $1.66 billion in cash and $85.85 million in debt, giving a net cash position of $1.58 billion or $12.14 per share.

Cash & Cash Equivalents	1.66B
Total Debt	85.85M
Net Cash	1.58B
Net Cash Per Share	$12.14
Equity (Book Value)	3.07B
Book Value Per Share	23.66
Working Capital	1.56B

Cash Flow

In the last 12 months, operating cash flow was -$459.55 million and capital expenditures -$104.61 million, giving a free cash flow of -$564.16 million.

Operating Cash Flow	-459.55M
Capital Expenditures	-104.61M
Free Cash Flow	-564.16M
FCF Per Share	-$4.35

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Vaxcyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-22.51%
Shareholder Yield	-22.51%
Earnings Yield	-9.99%
FCF Yield	-10.29%

Analyst Forecast

The average price target for Vaxcyte is $114.17, which is 170.29% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$114.17
Price Target Difference	170.29%
Analyst Consensus	Strong Buy
Analyst Count	8
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-12.29%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1